Last reviewed · How we verify

Kailera — Portfolio Competitive Intelligence Brief

Kailera pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
KAI-9531 KAI-9531 phase 3 PD-1 inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ASLAN Pharmaceuticals · 1 shared drug class
  2. ATGC Co., Ltd. · 1 shared drug class
  3. Addpharma Inc. · 1 shared drug class
  4. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  5. Akeso · 1 shared drug class
  6. Amgen · 1 shared drug class
  7. Asahi Kasei Pharma Corporation · 1 shared drug class
  8. 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kailera:

Cite this brief

Drug Landscape (2026). Kailera — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kailera. Accessed 2026-05-14.

Related